MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab
Go back to MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab| MACROGENICS (NASDAQ: MGNX) | Delayed: 4.15 +0.02 (0.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.13 | 52 Week High | $36.11 | |||
| Open | $4.12 | 52 Week Low | $14.84 | |||
| Day High | $4.17 | P/E | 10.64 | |||
| Day Low | $4.09 | EPS | $0.39 | |||
| Volume | 123,263 | |||||

